More than 50 biotech leaders and investors are urging the FDA to disregard a methodologically flawed report on mifepristone.

Our health care system needs to do a better job of diagnosing and supporting people with cannabis-related diseases,” a ...

The people most at risk from suicide aren’t adolescents in angst or those experiencing a midlife lull, but men age 75 and ...

A pioneering reproductive technology reduced the risk of children inheriting disease-causing mutations in mitochondria, ...

As mothers of children with this disease, we have wept helplessly in recent months as friends — fellow members of a club we ...

A new large study from Denmark finds no evidence that aluminum salts used in vaccines are tied to a higher risk of childhood ...

Robert F. Kennedy Jr. just named Mark Cruz, a Klamath member, his top tribal health adviser. In a Q&A, Cruz emphasized tribal ...

The FDA will request Sarepta Therapeutics stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, ...

A 51-year-old man died last month after receiving an experimental treatment from Sarepta, the third death this year tied to ...

A federal judge has tossed out a lawsuit from Humana that attempted to reinstate higher quality ratings to its 2025 Medicare ...

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...